Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Tarceva NDA accepted for priority review

Oct. 5, 2004

AP-23573 enters phase II study for bone and soft tissue sarcomas

Oct. 5, 2004

Multiple targets elucidated for anti-GI cancer agent HKH-40A

Oct. 5, 2004

Santaris describes novel potent Bcl-2 inhibitor SPC-2004

Oct. 5, 2004

ANG-704: A metabolically stable bioreductive prodrug of combretastatin A4

Oct. 5, 2004

French team identifies new G-quadruplex-binding telomerase inhibitors

Oct. 5, 2004

New antiangiogenic kinase inhibitors discovered at Cellular Genomics

Oct. 5, 2004

Boehringer Ingelheim scientists claim new antiproliferative agents

Oct. 5, 2004

Triple angiokinase inhibitor, BIBF-1120, shows promise for clinical development

Oct. 4, 2004

Studies show biological activity and tolerability of AZD-3409

Oct. 4, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...